These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25144635)

  • 1. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.
    Nissen A; Christensen M; Knop FK; Vilsbøll T; Holst JJ; Hartmann B
    J Clin Endocrinol Metab; 2014 Nov; 99(11):E2325-9. PubMed ID: 25144635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia.
    Christensen MB; Lund A; Calanna S; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2018 Jan; 103(1):288-294. PubMed ID: 29099978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of age and glycemic level on the response of the beta-cell to glucose-dependent insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin.
    Meneilly GS; Ryan AS; Minaker KL; Elahi D
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2925-32. PubMed ID: 9709971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes.
    Bergmann NC; Lund A; Gasbjerg LS; Jørgensen NR; Jessen L; Hartmann B; Holst JJ; Christensen MB; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2953-2960. PubMed ID: 30848791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
    Nauck M; Schmidt WE; Ebert R; Strietzel J; Cantor P; Hoffmann G; Creutzfeldt W
    J Clin Endocrinol Metab; 1989 Sep; 69(3):654-62. PubMed ID: 2668324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes.
    Christensen MB; Lund AB; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
    J Endocr Soc; 2020 Sep; 4(9):bvaa097. PubMed ID: 32904711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of gastrointestinal hormones in postprandial reduction of bone resorption.
    Henriksen DB; Alexandersen P; Bjarnason NH; Vilsbøll T; Hartmann B; Henriksen EE; Byrjalsen I; Krarup T; Holst JJ; Christiansen C
    J Bone Miner Res; 2003 Dec; 18(12):2180-9. PubMed ID: 14672353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
    Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
    Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of endogenous GIP in patients with type 2 diabetes.
    Stensen S; Gasbjerg LS; Krogh LL; Skov-Jeppesen K; Sparre-Ulrich AH; Jensen MH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Knop FK
    Eur J Endocrinol; 2021 May; 185(1):33-45. PubMed ID: 33886495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between Postprandial Gut Hormones and Markers of Bone Remodeling.
    Jensen NW; Clemmensen KKB; Jensen MM; Pedersen H; Færch K; Diaz LJ; Quist JS; Størling J
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
    Christensen MB; Calanna S; Holst JJ; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E418-26. PubMed ID: 24423311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans.
    Veedfald S; Vedtofte L; Skov-Jeppesen K; Deacon CF; Hartmann B; Vilsbøll T; Knop FK; Christensen MB; Holst JJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis.
    Helsted MM; Gasbjerg LS; Lanng AR; Bergmann NC; Stensen S; Hartmann B; Christensen MB; Holst JJ; Vilsbøll T; Rosenkilde MM; Knop FK
    Bone; 2020 Nov; 140():115553. PubMed ID: 32730920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects.
    Westberg-Rasmussen S; Starup-Linde J; Hermansen K; Holst JJ; Hartmann B; Vestergaard P; Gregersen S
    Bone; 2017 Apr; 97():261-266. PubMed ID: 28126633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans.
    Vollmer K; Gardiwal H; Menge BA; Goetze O; Deacon CF; Schmidt WE; Holst JJ; Meier JJ
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1379-85. PubMed ID: 19174495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH
    Gasbjerg LS; Hartmann B; Christensen MB; Lanng AR; Vilsbøll T; Jørgensen NR; Holst JJ; Rosenkilde MM; Knop FK
    Bone; 2020 Jan; 130():115079. PubMed ID: 31622777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of physiological hyperglycemia on duodenal motility and flow events, glucose absorption, and incretin secretion in healthy humans.
    Kuo P; Wishart JM; Bellon M; Smout AJ; Holloway RH; Fraser RJ; Horowitz M; Jones KL; Rayner CK
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3893-900. PubMed ID: 20501683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption.
    Mabilleau G; Perrot R; Mieczkowska A; Boni S; Flatt PR; Irwin N; Chappard D
    Bone; 2016 Oct; 91():102-12. PubMed ID: 27451082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.